• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[The efficacy and safety analysis of pomalidomide in the treatment of relapsed/refractory multiple myeloma].

作者信息

Lu J, He H Y, Li L, Qiang W T, Liu J, Guo P, Jiang H, Fu W J, Du J

机构信息

Department of Hematology, The Myeloma & Lymphoma Center, The Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital), Shanghai 200003, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2023 Jan 14;44(1):75-78. doi: 10.3760/cma.j.issn.0253-2727.2023.01.015.

DOI:10.3760/cma.j.issn.0253-2727.2023.01.015
PMID:36987729
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10067371/
Abstract
摘要

相似文献

1
[The efficacy and safety analysis of pomalidomide in the treatment of relapsed/refractory multiple myeloma].泊马度胺治疗复发/难治性多发性骨髓瘤的疗效与安全性分析
Zhonghua Xue Ye Xue Za Zhi. 2023 Jan 14;44(1):75-78. doi: 10.3760/cma.j.issn.0253-2727.2023.01.015.
2
Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.复发/难治性多发性骨髓瘤中isatuximab联合泊马度胺和地塞米松的预测生物标志物
Blood Cancer J. 2021 Mar 12;11(3):55. doi: 10.1038/s41408-021-00438-y.
3
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.英地昔单抗瑞妥昔单抗联合来那度胺或泊马度胺治疗复发/难治性多发性骨髓瘤的多中心 1/2a 期研究。
Lancet Haematol. 2021 Nov;8(11):e794-e807. doi: 10.1016/S2352-3026(21)00208-8. Epub 2021 Sep 13.
4
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.泊马度胺与低剂量地塞米松可改善复发/难治性多发性骨髓瘤患者的健康相关生活质量，并延长MM-003随机III期试验中患者病情恶化的时间。
Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):519-30. doi: 10.1016/j.clml.2015.05.007. Epub 2015 Jun 6.
5
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.isatuximab联合泊马度胺和地塞米松治疗复发/难治性老年多发性骨髓瘤患者：ICARIA-MM亚组分析
Haematologica. 2021 Apr 1;106(4):1182-1187. doi: 10.3324/haematol.2020.253450.
6
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.泊马度胺联合低剂量地塞米松与高剂量地塞米松单独用于治疗复发和难治性多发性骨髓瘤（MM-003）患者：一项随机、开放标签、3 期试验。
Lancet Oncol. 2013 Oct;14(11):1055-1066. doi: 10.1016/S1470-2045(13)70380-2. Epub 2013 Sep 3.
7
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.来那度胺治疗后复发或难治性多发性骨髓瘤患者的泊马度胺、硼替佐米和地塞米松治疗（OPTIMISMM）：一项随机、开放标签、3 期试验。
Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13.
8
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.依沙佐米联合泊马度胺和低剂量地塞米松与泊马度胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤患者（ICARIA-MM）：一项随机、多中心、开放性、3 期研究。
Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
9
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.来那度胺治疗后复发/难治性多发性骨髓瘤患者采用泊马度胺、地塞米松和达雷妥尤单抗治疗。
Leukemia. 2020 Dec;34(12):3286-3297. doi: 10.1038/s41375-020-0813-1. Epub 2020 May 6.
10
Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.isatuximab联合泊马度胺和地塞米松治疗复发/难治性多发性骨髓瘤虚弱患者：ICARIA-MM亚组分析
Am J Hematol. 2021 Nov 1;96(11):E423-E427. doi: 10.1002/ajh.26319. Epub 2021 Sep 23.

本文引用的文献

1
Pomalidomide-based therapy for extramedullary multiple myeloma.基于泊马度胺的疗法治疗髓外多发性骨髓瘤。
Hematology. 2022 Dec;27(1):88-94. doi: 10.1080/16078454.2021.2019364.
2
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.达雷妥尤单抗联合泊马度胺和地塞米松与泊马度胺和地塞米松单药治疗既往治疗的多发性骨髓瘤（APOLLO）：一项开放标签、随机、III 期临床试验。
Lancet Oncol. 2021 Jun;22(6):801-812. doi: 10.1016/S1470-2045(21)00128-5.
3
Multiple myeloma.多发性骨髓瘤。
Lancet. 2021 Jan 30;397(10272):410-427. doi: 10.1016/S0140-6736(21)00135-5.
4
American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.美国血液学会2020年静脉血栓栓塞管理指南：深静脉血栓形成和肺栓塞的治疗
Blood Adv. 2020 Oct 13;4(19):4693-4738. doi: 10.1182/bloodadvances.2020001830.
5
Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM.泊马度胺联合硼替佐米和地塞米松治疗复发或难治性多发性骨髓瘤：来自 OPTIMISMM 研究的日本亚组分析。
Cancer Sci. 2020 Jun;111(6):2116-2122. doi: 10.1111/cas.14415. Epub 2020 May 13.
6
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).泊马度胺、环磷酰胺和地塞米松治疗复发/难治性老年多发性骨髓瘤患者：韩国多发性骨髓瘤工作组（KMMWP-164 研究）。
Am J Hematol. 2020 Apr;95(4):413-421. doi: 10.1002/ajh.25726. Epub 2020 Jan 24.
7
Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network.泊马度胺与地塞米松联合环磷酰胺治疗复发/难治性多发性骨髓瘤（AMN001）：亚洲骨髓瘤网络试验。
Blood Cancer J. 2019 Oct 8;9(10):83. doi: 10.1038/s41408-019-0245-1.
8
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.来那度胺治疗后复发或难治性多发性骨髓瘤患者的泊马度胺、硼替佐米和地塞米松治疗（OPTIMISMM）：一项随机、开放标签、3 期试验。
Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13.
9
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.来那度胺、环磷酰胺和地塞米松治疗真实世界中复发/难治性多发性骨髓瘤患者：一项单中心回顾性研究。
Ann Hematol. 2019 Jun;98(6):1441-1447. doi: 10.1007/s00277-019-03649-3. Epub 2019 Mar 14.
10
Pomalidomide.泊马度胺
Recent Results Cancer Res. 2018;212:169-185. doi: 10.1007/978-3-319-91439-8_8.